119 related articles for article (PubMed ID: 12805159)
1. Public health and company wealth.
Ford N
BMJ; 2003 Jun; 326(7402):1296. PubMed ID: 12805159
[TBL] [Abstract][Full Text] [Related]
2. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
James JS
AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
[TBL] [Abstract][Full Text] [Related]
3. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544
[No Abstract] [Full Text] [Related]
4. [GlaxoSmithKline again lowers prices of drugs for HIV/AIDS and malaria].
Krankenpfl J; 2002; 40(7-9):222-3. PubMed ID: 12514863
[No Abstract] [Full Text] [Related]
5. Uganda cuts AIDS drug deal.
IAPAC Mon; 2001 Feb; 7(2):40. PubMed ID: 11302022
[No Abstract] [Full Text] [Related]
6. An unequal activism for an unequal epidemic?
Selemogo M
Dev World Bioeth; 2005 May; 5(2):153-68. PubMed ID: 15842724
[TBL] [Abstract][Full Text] [Related]
7. Essential AIDS medications in India.
Thomas J
Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
[No Abstract] [Full Text] [Related]
8. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
9. Embarrassed firms slash prices for AIDs drugs.
Boseley S
N Z Med J; 2001 Oct; 114(1141):440. PubMed ID: 11700768
[No Abstract] [Full Text] [Related]
10. Glaxo drops drug prices, AIDS foundation drops suit.
AIDS Policy Law; 2003 May; 18(10):6. PubMed ID: 12809097
[No Abstract] [Full Text] [Related]
11. Policy watch. Profitable pills.
Gebbie KM
AIDS Read; 2004 Mar; 14(3):106, 109. PubMed ID: 15067998
[No Abstract] [Full Text] [Related]
12. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
13. "We all have AIDS": case for reducing the cost of HIV drugs to zero.
Berwick D
BMJ; 2002 Jan; 324(7331):214-6. PubMed ID: 11809645
[No Abstract] [Full Text] [Related]
14. Commentary: the reality of treating HIV and AIDS in poor countries.
Sykes R
BMJ; 2002 Jan; 324(7331):216-7. PubMed ID: 11831203
[No Abstract] [Full Text] [Related]
15. Thank God for rich women with mustaches.
Friedman JH
Med Health R I; 2001 Jul; 84(7):222-3. PubMed ID: 11482273
[No Abstract] [Full Text] [Related]
16. Health, trade, and industry officials set to debate access to essential drugs.
Kapp C
Lancet; 2001 Apr; 357(9262):1105. PubMed ID: 11297977
[No Abstract] [Full Text] [Related]
17. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
18. Poor world health and rich world wealth.
Taylor D
BMJ; 2001 Mar; 322(7287):629-30. PubMed ID: 11250835
[No Abstract] [Full Text] [Related]
19. Access to HIV drugs: are we changing the two world paradigm?
Lazzarini Z
Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297
[No Abstract] [Full Text] [Related]
20. World Trade Organization still threatens supply of affordable AIDS drugs.
Hagmann M
Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
[No Abstract] [Full Text] [Related]
[Next] [New Search]
